WALTHAM, Mass., March 5 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) today reported a restructuring of its Board of
Directors.  Five new members have been appointed to the eight person Board of
Directors, effective immediately.  They are J. Joseph Marr, M.D. acting
President and Chief Executive Officer of ImmuLogic; C. Garrison Fathman, M.D.,
Professor, Department of Medicine, Stanford University School of Medicine;
Carl Goldfischer, M.D., Chief Financial Officer, Vice President Finance and
Strategic Planning, of ImClone Systems Inc.; Geraldine Henwood, Chief
Executive Officer of IBAH, Inc.; and Richard Pops, Chief Executive Officer of
Alkermes Inc.  These appointments follow the resignation of Malcolm Gefter,
Ph.D., Chairman of the Board and scientific founder, Alan Dalby, Howard
Jacobson, Kenneth Melmon, M.D., and Larry Soll, Ph.D.  Two individuals,
appointed to the Board in September 1996, will continue as Directors, they are
Samuel Fleming, Chairman and Chief Executive Officer of Decision Resources,
Inc. and Paul Friedman, M.D., President of Dupont Merck Research Labs.
    "This restructuring was done in consultation with several major
stockholders with the purpose of adding pharmaceutical and business advisory
capabilities to the Board.  The newly constituted Board has the diversity of
talent and experience needed to guide ImmuLogic at its present stage of
development," said Dr. Joseph Marr, acting President and Chief Executive
Officer.  "We thank the Board members who are stepping down for their
contributions to the company over the last several years.  We would like
especially to acknowledge Dr. Malcolm Gefter for his scientific and business
contributions since he founded the Company in 1987."
    The Company has entered into a severance agreement with Dr. Gefter
providing for payments commensurate with those otherwise due under his
employment contract.
    ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Masschusetts, specializing in the development of peptide
immunotherapeutics, with a primary focus on allergies, including cat and
ragweed allergies, and autoimmune diseases such as multiple sclerosis.  The
company also is developing a cocaine vaccine.  The company's press releases
are available through Company News on Call by fax at 800-758-5804,
ext. 114501, and on the Internet at http://www.prnewswire.com.

Link to this page: